Medicare’s experiment to repair kidney failure to finish early
The Facilities for Medicare and Medicaid Providers will reduce brief an enormous experiment to attempt to change the way in which dialysis is finished within the U.S. The company, led by Mehmet Oz, will finish its Finish-Stage Renal Illness Therapy Selections (ETC) mannequin on Dec. 31, in response to a ultimate rule revealed within the Federal Register final week.
The trial, run by the CMS Innovation Heart, was testing whether or not giving monetary incentives to suppliers would transfer extra sufferers with end-stage kidney illness onto house dialysis and thru the transplant course of. It was the largest such experiment within the historical past of American well being care, and required 30% of the nation’s dialysis suppliers to take part.
Nonetheless, ETC hasn’t confirmed that strategy works. An evaluation after the primary yr, 2021, confirmed no influence on house dialysis or transplantation. A research final summer season discovered the same end result. Suppliers taking part within the new cost mannequin weren’t getting extra sufferers onto house dialysis or to transplant than these within the management group, the paper reported.
This text is unique to STAT+ subscribers
Unlock this text — plus in-depth evaluation, newsletters, premium occasions, and information alerts.
Have already got an account? Log in
To learn the remainder of this story subscribe to STAT+.
